Literature DB >> 6145190

Benzodiazepine dependence.

M Lader.   

Abstract

Dependence to benzodiazepines is difficult to induce in animals but has been induced by high doses in man. Case reports of benzodiazepine dependence are rare compared with the usage of these drugs, but provide no proper epidemiological framework for the estimation of risk. Patients taking these drugs for four months or more may develop symptoms on withdrawal, characterized by anxiety, dysphoria, malaise, depersonalization, and by perceptual changes such as hyperacusis and unsteadiness. In our first study we compared four patients withdrawing from high doses of benzodiazepines with six patients withdrawing from therapeutic doses. In all patients the typical withdrawal syndrome was noted and was equal in intensity in both groups. In the second study, long-term, normal-dose benzodiazepine treatment was discontinued in 24 patients believed to be dependent on their medication. The withdrawal was gradual, placebo-controlled and double-blind. All experienced some form of withdrawal reaction, which ranged from anxiety and dysphoria to moderate affective and perceptual changes. Symptom ratings rose as the drugs were discontinued, but usually subsided to pre-withdrawal levels over the next two to four weeks. Electroencephalograhic (EEG) changes comprised marked reduction in fast-wave activity as the drugs were withdrawn, and an improvement in psychological performance was noted. It is concluded that a risk of dependencies present in all patients taking benzodiazepines even in therapeutic doses for more than a few months. Caution is urged in the prescribing of these drugs.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6145190     DOI: 10.1016/0278-5846(84)90139-8

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  7 in total

1.  Are benzodiazepines antidepressants?

Authors:  G Laakmann; M Faltermaier-Temizel; S Bossert-Zaudig; T Baghai
Journal:  Psychopharmacology (Berl)       Date:  1996-04       Impact factor: 4.530

2.  Evaluation in rats of the somnogenic, pyrogenic, and central nervous system depressant effects of muramyl dipeptide.

Authors:  L T Meltzer; K A Serpa; W H Moos
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Patterns and correlates of benzodiazepine use in the French general population.

Authors:  Rajaa Lagnaoui; Fanny Depont; Annie Fourrier; Abdelillah Abouelfath; Bernard Bégaud; Hélène Verdoux; Nicholas Moore
Journal:  Eur J Clin Pharmacol       Date:  2004-09       Impact factor: 2.953

4.  Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo.

Authors:  G Laakman; M Faltermaier-Temizel; S Bossert-Zaudig; T Baghai; G Lorkowski
Journal:  Psychopharmacology (Berl)       Date:  1995-07       Impact factor: 4.530

5.  Benzodiazepine use among adults residing in the urban settlements of Karachi, Pakistan: a cross sectional study.

Authors:  Saleem P Iqbal; Syed Ahmer; Salima Farooq; Yasmin Parpio; Ambreen Tharani; Rashid A M Khan; Mohammad Zaman
Journal:  Subst Abuse Treat Prev Policy       Date:  2011-08-01

6.  Pattern of benzodiazepine use in psychiatric outpatients in Pakistan: a cross-sectional survey.

Authors:  Syed Ahmer; Sumera Salamat; Rashid Am Khan; Saleem Perwaiz Iqbal; Imran Ijaz Haider; Ayesha Shabaz Khan; Mohsan Zafar
Journal:  Clin Pract Epidemiol Ment Health       Date:  2009-04-28

7.  Awareness and use of Benzodiazepines in healthy volunteers and ambulatory patients visiting a tertiary care hospital: a cross sectional survey.

Authors:  Mustafa Raoof; Haq Nawaz; Rabeeya Nusrat; Aqueel Hussain Pabaney; Ali Raza Randhawa; Rabeea Rehman; Nida Butool Rizvi; Haider Naqvi
Journal:  PLoS One       Date:  2008-03-19       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.